Literature DB >> 30352892

Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series.

Javier Narváez1, Judit LLuch2, Juan José Alegre Sancho3, Maria Molina-Molina4, Joan Miquel Nolla2, Ivan Castellví5.   

Abstract

Entities:  

Keywords:  Treatment; pulmonary fibrosis; systemic sclerosis

Mesh：

Substances：

Year:  2018        PMID： 30352892     DOI： 10.1136/annrheumdis-2018-214449

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

Review 1.  Systemic sclerosis (scleroderma): remaining challenges.

Authors:  Mary Karin Connolly
Journal:  Ann Transl Med       Date:  2021-03

2.  Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study.

Authors:  Hana Štorkánová; Sabína Oreská; Maja Špiritović; Barbora Heřmánková; Kristýna Bubová; Martin Komarc; Karel Pavelka; Jiří Vencovský; Jörg H W Distler; Ladislav Šenolt; Radim Bečvář; Michal Tomčík
Journal:  Sci Rep       Date:  2021-01-07       Impact factor: 4.379

Review 3.  Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?

Authors:  Anca Cardoneanu; Alexandra Maria Burlui; Luana Andreea Macovei; Ioana Bratoiu; Patricia Richter; Elena Rezus
Journal:  Biomedicines       Date:  2022-01-29

Review 4.  Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review.

Authors:  Corrado Campochiaro; Maria Grazia Lazzaroni; Cosimo Bruni; Elisabetta Zanatta; Giacomo De Luca; Marco Matucci-Cerinic
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-08-22       Impact factor: 3.625
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.